These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 8636681

  • 1. Appetite suppressants as adjuncts in the treatment of obesity.
    Elks ML.
    J Fam Pract; 1996 Mar; 42(3):287-92. PubMed ID: 8636681
    [Abstract] [Full Text] [Related]

  • 2. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 4. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 5. Medical interventions in adolescent obesity.
    Khan UI, Collier M.
    Adolesc Med State Art Rev; 2008 Dec; 19(3):406-20, viii. PubMed ID: 19227383
    [Abstract] [Full Text] [Related]

  • 6. Management of obesity: medical treatment options.
    Carek PJ, Sherer JT, Carson DS.
    Am Fam Physician; 1997 Feb 01; 55(2):551-8, 561-2. PubMed ID: 9054224
    [Abstract] [Full Text] [Related]

  • 7. [Anti-obesity drugs--mechanism and medical indication of appetite suppressants].
    Nishida M.
    Nihon Rinsho; 2001 Mar 01; 59(3):620-4. PubMed ID: 11268619
    [Abstract] [Full Text] [Related]

  • 8. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH, Fernstrom JD.
    Int J Clin Pract; 2002 Nov 01; 56(9):683-6. PubMed ID: 12469983
    [Abstract] [Full Text] [Related]

  • 9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 01; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 10. [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].
    Rajzer M, Wojciechowska W, Kawecka-Jaszcz K.
    Przegl Lek; 2004 Jan 01; 61(2):94-8. PubMed ID: 15230149
    [Abstract] [Full Text] [Related]

  • 11. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar 01; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 12. Medical strategies for weight loss in the overweight and obese patient.
    Di Caro S, Hamad GG, Fernstrom MH, Schauer PR, Bonanomi G.
    Minerva Gastroenterol Dietol; 2006 Dec 01; 52(4):415-30. PubMed ID: 17108871
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined dietary and pharmacological weight management in obese hypopituitary patients.
    Mersebach H, Klose M, Svendsen OL, Astrup A, Feldt-Rasmussen U.
    Obes Res; 2004 Nov 01; 12(11):1835-43. PubMed ID: 15601980
    [Abstract] [Full Text] [Related]

  • 15. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug 01; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 16. Combining behavioral and pharmacological treatments for obesity.
    Phelan S, Wadden TA.
    Obes Res; 2002 Jun 01; 10(6):560-74. PubMed ID: 12055334
    [Abstract] [Full Text] [Related]

  • 17. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 01; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 18. Treatment of obesity with "combination" pharmacotherapy.
    Rothman RB.
    Am J Ther; 2010 Sep 01; 17(6):596-603. PubMed ID: 19352140
    [Abstract] [Full Text] [Related]

  • 19. [Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
    Payer J, Hainer V, Ondrejka P, Kajtor Z.
    Vnitr Lek; 2004 Nov 01; 50(11):825-9. PubMed ID: 15648961
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z, Placha G.
    J Hum Hypertens; 2005 Sep 01; 19(9):737-43. PubMed ID: 15905888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.